MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

7.540 +0.140 (+1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports First Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Puma Biotechnology (NASDAQ:PBYI) ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
News headline image
Puma Biotechnology's Earnings: A Preview ↗
Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Stealth BioTherapeutics (NASDAQ:MITO 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Good morning, investor! We're starting off the day right with a look at the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
News headline image
20 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-... 
Via Benzinga
News headline image
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer ↗
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Biomerica (NASDAQ:BMRA) stock inc... 
Via Benzinga
News headline image
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Releases Updated Corporate Presentation
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
News headline image
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial ↗
Puma Biotechnology Inc (NASDAQ: PBYI) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story